Delivering extraordinary. Empowering ordinary.
We’re developing novel oral medicines for rare diseases to help patients take part in the everyday activities they enjoy.
Learn MoreStructure-guided Drug Design
We combine traditional cell biology with medicinal chemistry to build synthetic compounds that bind to specific protein targets to fight disease.
See Our ScienceBuilding a Rare Disease Drug Portfolio
We are developing a pipeline of oral drugs for rare diseases, including our next generation kallikrein inhibitor for hereditary angioedema (HAE).
View Our PipelineRecent News
Stay up to date with the latest discoveries, events, and reports from BioCryst.
-
BioCryst Receives Additional $3.5 Million to Fund Clinical Trials of Galidesivir in Yellow Fever
-
CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile
-
CORRECTION -- BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks
Join Our Team
We are a collection of passionate individuals united by a commitment to scientific excellence and an unwavering focus on the needs of patients.
JOB OPENINGS